

Publications auxquelles l'Aretasc a participé en 2014

- 1- Phase III study of Vinflunine plus Gemcitabine versus Paclitaxel plus Gemcitabine in first –line treatment of anthracycline pretreated advanced breast cancer.
Study Victoria: Abstract Asco 2014.
- 2- Nanobitic sélectionnée pour présenter les données de l'étude de NBTXR3 lors de la 50 ème conférence Asco: Chicago June 2- 2014 poster
- 3- Phase II study of cetuximab pemetrexed, cisplatin and concurrent radiotherapie in patients with locally advanced, unresectable stage III, non-squamous non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial ;abstract discussion session S405, Asco June 1- Chicago 2014.
- 4 - Hormonothérapie des cancers du sein. Quoi de neuf ? ▶ LA
LETTRE DU CHIRURGIEN : GENESIS — N° 181 —
Octobre/Novembre 2014 • 11
JMVannetzel, JF Llory, E Sebban.
- 5 – Second line therapy in elderly patients with advanced non small cell lung cancer.
Quoix E, Westeel V, Moreau L.
European Respiratory Journal 2014, 43 : 240-249.
- 6- Oxaliplatin, fluorouracil and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8) : an open – label, randomised phase « trial. Taieb J, Tabernero J, Subtil F
Pettac -8 Study investigators. Lancet Oncol. 2014 Jul ;15(8) :862-73.
- 7- Prognostic value of KRAS mutations in stage III colon cancer : post-hoc analysis of the PETTAC 8 phase III trial dataset.
Blons H, Emile JF, Le Malicot K. Ann Oncol. 2014 ;Dec ;25(12) 2378-85